Reason for request

Modification of inclusion

Summary of opinion

Favourable opinion for maintenance of reimbursement for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B, in accordance with the HAS vaccine recommendations of 7 March 2024 and 27 June 2024.


Clinical Benefit

Substantial

The Committee deems that updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical benefit, which remains substantial in the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.


Clinical Added Value

important

The vaccine strategy update in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical added value in the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B (important clinical added value (CAV II) in individuals from the age of 2 months and older according to the opinion of 25 June 2014).